Addex Free Cash Flow Yield vs Book Value Per Share Analysis

ADXN Stock

USD 10.60 0.76 7.72%

Addex Therapeutics financial indicator trend analysis is way more than just evaluating Addex Therapeutics prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Addex Therapeutics is a good investment. Please check the relationship between Addex Therapeutics Free Cash Flow Yield and its Book Value Per Share accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Addex Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in interest.

To learn how to invest in Addex Stock, please use our How to Invest in Addex Therapeutics guide.

Free Cash Flow Yield vs Book Value Per Share

Free Cash Flow Yield vs Book Value Per Share Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Addex Therapeutics Free Cash Flow Yield account and Book Value Per Share. At this time, the significance of the direction appears to have pay attention.

The correlation between Addex Therapeutics' Free Cash Flow Yield and Book Value Per Share is -0.95. Overlapping area represents the amount of variation of Free Cash Flow Yield that can explain the historical movement of Book Value Per Share in the same time period over historical financial statements of Addex Therapeutics, assuming nothing else is changed. The correlation between historical values of Addex Therapeutics' Free Cash Flow Yield and Book Value Per Share is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Free Cash Flow Yield of Addex Therapeutics are associated (or correlated) with its Book Value Per Share. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Book Value Per Share has no effect on the direction of Free Cash Flow Yield i.e., Addex Therapeutics' Free Cash Flow Yield and Book Value Per Share go up and down completely randomly.

Correlation Coefficient

-0.95

Relationship Direction	Negative
Relationship Strength	Significant

View All Relationships

Free Cash Flow Yield

A financial solvency ratio that compares the free cash flow per share a company is expected to earn against its market value per share, calculated as free cash flow per share divided by market price per share.

Book Value Per Share

The ratio of equity available to common shareholders divided by the number of outstanding shares. This measure represents the value per share of a company according to its financial statements.

Most indicators from Addex Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Addex Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Addex Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in interest.

To learn how to invest in Addex Stock, please use our How to Invest in Addex Therapeutics guide.As of the 23rd of September 2024, Enterprise Value is likely to grow to about 541.5 M, while Selling General Administrative is likely to drop about 4.7 M.

Addex Therapeutics fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Common Stock Total Equity	Common Stock Shares Outstanding	Other Current Assets	Other Stockholder Equity	Total Liab	Property Plant And Equipment Gross	Total Current Assets	Short Term Debt	Intangible Assets	Common Stock	Non Current Liabilities Total	Net Receivables
Total Assets		-0.24	0.54	0.67	0.99	0.71	0.08	-0.99	0.57	0.58	0.99	0.54	0.08	0.99	-0.11	-0.34	-0.15	-0.43	0.66	0.25	1.0	0.06	-0.19	0.31	0.37	0.45
Short Long Term Debt Total	-0.24		0.08	-0.08	-0.27	-0.42	0.13	0.23	-0.43	-0.46	-0.23	-0.19	0.25	-0.23	-0.04	-0.23	-0.26	0.51	0.03	-0.64	-0.23	-0.28	0.01	0.38	0.34	-0.33
Other Current Liab	0.54	0.08		0.88	0.46	0.79	-0.25	-0.45	0.25	0.01	0.45	0.8	0.5	0.45	-0.27	-0.27	-0.04	-0.03	0.81	0.44	0.47	-0.15	-0.41	-0.1	0.27	0.65
Total Current Liabilities	0.67	-0.08	0.88		0.58	0.75	0.12	-0.61	0.17	0.42	0.61	0.66	0.26	0.61	0.07	-0.03	-0.01	-0.03	0.97	0.54	0.63	0.25	-0.13	0.09	0.55	0.51
Total Stockholder Equity	0.99	-0.27	0.46	0.58		0.67	0.05	-0.99	0.61	0.56	0.99	0.51	0.05	0.99	-0.14	-0.36	-0.16	-0.48	0.56	0.2	0.99	0.01	-0.2	0.3	0.29	0.43
Property Plant And Equipment Net	0.71	-0.42	0.79	0.75	0.67		-0.25	-0.63	0.7	0.22	0.62	0.9	0.38	0.62	-0.44	-0.39	-0.09	-0.57	0.64	0.5	0.64	-0.13	-0.52	-0.22	0.07	0.78
Current Deferred Revenue	0.08	0.13	-0.25	0.12	0.05	-0.25		-0.14	-0.28	0.5	0.15	-0.44	-0.55	0.15	0.55	0.27	-0.05	0.21	0.26	-0.2	0.14	0.66	0.65	0.45	0.63	-0.51
Net Debt	-0.99	0.23	-0.45	-0.61	-0.99	-0.63	-0.14		-0.53	-0.6	-1.0	-0.44	0.02	-1.0	0.04	0.3	0.16	0.4	-0.61	-0.2	-1.0	-0.09	0.11	-0.36	-0.37	-0.36
Retained Earnings	0.57	-0.43	0.25	0.17	0.61	0.7	-0.28	-0.53		0.14	0.53	0.64	0.29	0.53	-0.76	-0.74	-0.25	-0.92	0.07	-0.01	0.53	-0.41	-0.66	-0.17	-0.28	0.59
Accounts Payable	0.58	-0.46	0.01	0.42	0.56	0.22	0.5	-0.6	0.14		0.61	0.01	-0.31	0.61	0.42	0.18	0.13	-0.2	0.47	0.4	0.61	0.69	0.31	0.46	0.46	0.03
Cash	0.99	-0.23	0.45	0.61	0.99	0.62	0.15	-1.0	0.53	0.61		0.43	-0.03	1.0	-0.03	-0.29	-0.15	-0.4	0.61	0.21	1.0	0.11	-0.1	0.37	0.38	0.35
Non Current Assets Total	0.54	-0.19	0.8	0.66	0.51	0.9	-0.44	-0.44	0.64	0.01	0.43		0.75	0.43	-0.6	-0.5	-0.15	-0.49	0.55	0.33	0.45	-0.35	-0.73	-0.29	0.0	0.84
Non Currrent Assets Other	0.08	0.25	0.5	0.26	0.05	0.38	-0.55	0.02	0.29	-0.31	-0.03	0.75		-0.03	-0.59	-0.46	-0.16	-0.16	0.2	-0.05	-0.01	-0.53	-0.76	-0.27	-0.1	0.59
Cash And Short Term Investments	0.99	-0.23	0.45	0.61	0.99	0.62	0.15	-1.0	0.53	0.61	1.0	0.43	-0.03		-0.03	-0.29	-0.15	-0.4	0.61	0.21	1.0	0.11	-0.1	0.37	0.38	0.35
Common Stock Total Equity	-0.11	-0.04	-0.27	0.07	-0.14	-0.44	0.55	0.04	-0.76	0.42	-0.03	-0.6	-0.59	-0.03		0.87	0.25	0.64	0.17	0.29	-0.04	0.79	0.84	0.33	0.49	-0.54
Common Stock Shares Outstanding	-0.34	-0.23	-0.27	-0.03	-0.36	-0.39	0.27	0.3	-0.74	0.18	-0.29	-0.5	-0.46	-0.29	0.87		0.23	0.58	0.0	0.42	-0.3	0.61	0.71	-0.09	0.16	-0.41
Other Current Assets	-0.15	-0.26	-0.04	-0.01	-0.16	-0.09	-0.05	0.16	-0.25	0.13	-0.15	-0.15	-0.16	-0.15	0.25	0.23		0.32	-0.08	0.38	-0.15	0.31	0.2	-0.27	-0.27	0.14
Other Stockholder Equity	-0.43	0.51	-0.03	-0.03	-0.48	-0.57	0.21	0.4	-0.92	-0.2	-0.4	-0.49	-0.16	-0.4	0.64	0.58	0.32		0.05	0.02	-0.4	0.31	0.55	0.11	0.27	-0.47
Total Liab	0.66	0.03	0.81	0.97	0.56	0.64	0.26	-0.61	0.07	0.47	0.61	0.55	0.2	0.61	0.17	0.0	-0.08	0.05		0.46	0.63	0.36	-0.03	0.27	0.72	0.37
Property Plant And Equipment Gross	0.25	-0.64	0.44	0.54	0.2	0.5	-0.2	-0.2	-0.01	0.4	0.21	0.33	-0.05	0.21	0.29	0.42	0.38	0.02	0.46		0.22	0.43	0.1	-0.18	0.05	0.41
Total Current Assets	1.0	-0.23	0.47	0.63	0.99	0.64	0.14	-1.0	0.53	0.61	1.0	0.45	-0.01	1.0	-0.04	-0.3	-0.15	-0.4	0.63	0.22		0.1	-0.11	0.36	0.39	0.37
Short Term Debt	0.06	-0.28	-0.15	0.25	0.01	-0.13	0.66	-0.09	-0.41	0.69	0.11	-0.35	-0.53	0.11	0.79	0.61	0.31	0.31	0.36	0.43	0.1		0.58	0.37	0.59	-0.36
Intangible Assets	-0.19	0.01	-0.41	-0.13	-0.2	-0.52	0.65	0.11	-0.66	0.31	-0.1	-0.73	-0.76	-0.1	0.84	0.71	0.2	0.55	-0.03	0.1	-0.11	0.58		0.32	0.32	-0.59
Common Stock	0.31	0.38	-0.1	0.09	0.3	-0.22	0.45	-0.36	-0.17	0.46	0.37	-0.29	-0.27	0.37	0.33	-0.09	-0.27	0.11	0.27	-0.18	0.36	0.37	0.32		0.72	-0.38
Non Current Liabilities Total	0.37	0.34	0.27	0.55	0.29	0.07	0.63	-0.37	-0.28	0.46	0.38	0.0	-0.1	0.38	0.49	0.16	-0.27	0.27	0.72	0.05	0.39	0.59	0.32	0.72		-0.21
Net Receivables	0.45	-0.33	0.65	0.51	0.43	0.78	-0.51	-0.36	0.59	0.03	0.35	0.84	0.59	0.35	-0.54	-0.41	0.14	-0.47	0.37	0.41	0.37	-0.36	-0.59	-0.38	-0.21

Click cells to compare fundamentals

Addex Therapeutics Account Relationship Matchups

Addex Therapeutics fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	33.0M	20.2M	22.5M	8.3M	4.6M	4.4M
Other Current Liab	2.0M	1.5M	2.1M	1.7M	1.4M	1.3M
Total Current Liabilities	5.7M	3.6M	4.1M	3.3M	2.9M	4.0M
Total Stockholder Equity	25.5M	14.6M	16.9M	4.9M	1.1M	1.1M
Property Plant And Equipment Net	571.0K	633.1K	542.1K	398.7K	352.9K	335.3K
Current Deferred Revenue	212.7K	1.1M	820.1K	235.0K	270.2K	412.9K
Net Debt	(31.0M)	(18.1M)	(20.0M)	(6.6M)	(3.5M)	(3.7M)
Retained Earnings	(300.8M)	(313.7M)	(329.1M)	(349.9M)	(360.4M)	(378.4M)
Accounts Payable	2.2M	983.5K	1.8M	1.3M	984.4K	913.8K
Cash	31.5M	18.7M	20.5M	7.0M	3.9M	3.7M
Non Current Assets Total	639.9K	692.2K	600.0K	453.1K	407.3K	386.9K
Non Currrent Assets Other	68.9K	59.1K	57.9K	54.4K	54.3K	51.6K
Cash And Short Term Investments	31.6M	18.8M	20.5M	7.0M	3.9M	3.7M
Common Stock Shares Outstanding	26.4M	26.7M	34.1M	45.2M	74.3M	78.0M
Liabilities And Stockholders Equity	33.0M	20.2M	22.5M	8.3M	4.6M	4.4M
Other Current Assets	734.0K	498.4K	1.1M	871.9M	217.0K	206.2K
Other Stockholder Equity	286.4M	286.9M	272.3M	327.9M	329.9M	288.6M
Total Liab	7.5M	5.6M	5.6M	3.4M	3.5M	4.5M
Property Plant And Equipment Gross	571.0K	633.1K	4.3M	4.4M	4.7M	2.4M
Total Current Assets	32.4M	19.5M	21.9M	7.8M	4.2M	4.0M
Short Term Debt	373.0K	308.6K	287.7K	286.1K	274.0K	193.4K
Non Current Liabilities Total	1.8M	2.0M	1.5M	87.0K	603.1K	761.6K
Accumulated Other Comprehensive Income	7.1M	8.6M	24.4M	25.8M	29.8M	31.3M
Net Receivables	118.0K	68.4K	324.4K	598.3K	151.3K	271.7K
Other Liab	639.4K	1.6M	1.7M	1.3M	1.5M	813.2K
Net Tangible Assets	25.5M	14.6M	16.9M	4.9M	5.6M	5.4M
Other Assets	68.9K	59.1K	57.9K	54.4K	48.9K	66.0K
Short Term Investments	14.0K	64.9K	17.1K	3.2K	848.0	805.6
Property Plant Equipment	571.0K	633.1K	542.1K	398.7K	458.5K	275.1K
Net Invested Capital	25.5M	14.6M	16.9M	4.9M	1.1M	1.1M
Net Working Capital	26.7M	15.9M	17.8M	4.5M	1.3M	1.3M

Additional Information and Resources on Investing in Addex Stock

When determining whether Addex Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Addex Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Addex Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Addex Therapeutics Stock:

How To Invest In Addex

Details

Is Addex Stock a good investment?

Details

What is Addex Therapeutics' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Addex Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in interest.

To learn how to invest in Addex Stock, please use our How to Invest in Addex Therapeutics guide.

You can also try the Bond Analysis module to evaluate and analyze corporate bonds as a potential investment for your portfolios..

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Addex Therapeutics. If investors know Addex will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Addex Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(19.82)

Revenue Per Share

2.04

Quarterly Revenue Growth

(0.53)

Return On Assets

(1.26)

Return On Equity

(8.10)

The market value of Addex Therapeutics is measured differently than its book value, which is the value of Addex that is recorded on the company's balance sheet. Investors also form their own opinion of Addex Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Addex Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Addex Therapeutics' market value can be influenced by many factors that don't directly affect Addex Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Addex Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Addex Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Addex Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Addex Free Cash Flow Yield vs Book Value Per Share Analysis

Free Cash Flow Yield vs Book Value Per Share

Free Cash Flow Yield vs Book Value Per Share Correlation Analysis

Correlation Coefficient

Free Cash Flow Yield

Book Value Per Share

Addex Therapeutics fundamental ratios Correlations

Addex Therapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Addex Therapeutics fundamental ratios Accounts

Additional Information and Resources on Investing in Addex Stock

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Current Assets	+ 1.0	Total Assets
Cash And Short Term Investments	+ 1.0	Cash
Total Current Assets	+ 1.0	Cash
Total Current Assets	+ 1.0	Cash And Short Term Investments
Total Stockholder Equity	+ 0.99	Total Assets
Cash	+ 0.99	Total Assets

Total Current Assets	- 1.0	Net Debt
Cash And Short Term Investments	- 1.0	Net Debt
Cash	- 1.0	Net Debt
Net Debt	- 0.99	Total Stockholder Equity
Net Debt	- 0.99	Total Assets
Other Stockholder Equity	- 0.92	Retained Earnings